Q04695
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
cytokeratin 17
NCBI Official Synonym Full Names
keratin 17
NCBI Protein Information
keratin, type I cytoskeletal 17; 39.1; CK-17; keratin-17; cytokeratin-17; OTTHUMP00000164770
UniProt Protein Name
Keratin, type I cytoskeletal 17
UniProt Synonym Protein Names
39.1; Cytokeratin-17; CK-17; Keratin-17
UniProt Entry Name
K1C17_HUMAN
NCBI Summary for KRT17
This gene encodes the type I intermediate filament chain keratin 17, expressed in nail bed, hair follicle, sebaceous glands, and other epidermal appendages. Mutations in this gene lead to Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex. [provided by RefSeq]
UniProt Comments for KRT17
K17: a type I cytoskeletal keratin. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. There are two types of cytoskeletal and microfibrillar keratin: type I (acidic; 40-55 kDa) [K9 to K20] and type II (neutral to basic; 56-70 kDa) [K1 to K8]. Both a basic and an acidic keratin are required for filament assembly. Generally associates with K6.
Protein type: Cytoskeletal
Chromosomal Location of Human Ortholog: 17q21.2
Cellular Component: cytoplasm; intermediate filament
Molecular Function: MHC class II receptor activity; protein binding; structural constituent of cytoskeleton; MHC class II protein binding
Biological Process: positive regulation of hair follicle development; epidermis development; hair follicle morphogenesis; positive regulation of translation; keratinization; intermediate filament organization; signal transduction; positive regulation of cell growth
Disease: Steatocystoma Multiplex; Pachyonychia Congenita 2
Product References and Citations for anti-KRT17 antibody
Guelstein, V. I., Tchypysheva, T. A., Ermilova, V. D., Litvinova, L. V., Troyanovsky, S. M., Bannikov, G. A. (1988). Monoclonal antibody mapping of keRatins 8 and 17 and of vimentin in normal Human mammary gland, benign tumors, dysplasias and breast cancer, Int J Cancer 42, 147-53. Troyanovsky, S. M., Guelstein, V. I., Tchipysheva, T. A., Krutovskikh, V. A., Bannikov, G. A. (1989). Patterns of expression of keRatin 17 in Human epithelia: dependency on cell position, J Cell Sci 93, 419-26. Wetzels, R. H., Kuijpers, H. J., Lane, E. B., Leigh, I. M., Troyanovsky, S. M., Holland, R., van Haelst, U. J., and Ramaekers, F. C. (1991). Basal cell-specific and hyperprolifeRation-related keRatins in Human breast cancer. Am J Pathol 138, 751-63. Moll, I., Moll, R. (1991). CompaRative cytokeRatin analysis of sweat gland ducts and eccrine poromas. Arch Dermatol Res. 283, 300-09. De Jong, E., van Vlijmen, I., van Erp, P., Ramaekers, F., Troyanowsky, S., Van de Kerkhof, P. (1991). Monoclonal anti-keRatin 17: A useful marker for anti-psoriatic therapies. Arch Dermatol Res 283, 480-82. Smedts, F., Ramaekers, F., Troyanovsky, S., Pruszczynski, M., Link, M., Lane, B., Leigh, I., and Vooijs, P. (1992). KeRatin expression in cervical cancer, Am J Pathol 141, 497-511. Wetzels, R. H., Schaafsma, H. E., Leigh, I. M., Lane, E. B., Troyanovsky, S. M., Wagenaar, S. S., Vooijs, G. P., and Ramaekers, F. C. (1992). Laminin and type VII collagen distribution in different types of Human lung carcinoma: correlation with expression of keRatins 14, 16, 17 and 18. Histopathology 20, 295-303. Smedts, F., Ramaekers, F., Troyanovsky, S., Pruszczynski, M., Robben, H., Lane, B., Leigh, I., Plantema, F., and Vooijs, P. (1992). Basal-cell keRatins in cervical reserve cells and a comparison to their expression in cervical intraepithelial neoplasia. Am J Pathol 140, 601-12. Smedts, F., Ramaekers, F., Link, M., Lauerova, L., Troyanovsky, S., Schijf, C., and Vooijs, G. P. (1994). Detection of keRatin subtypes in routinely processed cervical tissue: impliCations for tumour classifiCation and the study of cervix cancer aetiology. Virchows Arch 425, 145-155. Demirkesen, C., Hoede, N., Moll, R. (1995). Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeRatins. J Cutan Pathol 22, 518-35. Moll, R., et al. (1995). Differenzierungsmarker bei gynäkologischen Tumoren: Methodische und diagnostische Aspekte. In: Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie. W Zuckschwerdt Verlag. Litvinov, S. V., van Driel, W., van Rhijn, C. M., Bakker, H. A., van Krieken, H., Fleuren, G. J., and Warnaar, S. O. (1996). Expression of Ep-CAM in cervical squamous epithelia correlates with an increased prolifeRation and the disappearance of markers for terminal differentiation. Am J Pathol 148, 865-75.
Research Articles on KRT17
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-KRT17 antibody
Pathways associated with anti-KRT17 antibody
Diseases associated with anti-KRT17 antibody
Organs/Tissues associated with anti-KRT17 antibody
|